Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2021

17 - 21 Sep 2021
Paris Expo Porte de Versailles, Paris, France
Advances in prostate cancer in the last 10 years and a glimpse to the future
Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono
Advances in prostate cancer in the last 10 years and a glimpse to the future ( Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono )
21 Oct 2021
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatmen...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )
11 Oct 2021
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastati...
Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer ( Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain )
30 Sep 2021
ESMO 2021: PARPi data and their role in mono/combination therapies
Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong
ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )
29 Sep 2021
Radioembolisation with chemotherapy for colorectal liver metastases
Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA
Radioembolisation with chemotherapy for colorectal liver metastases ( Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA )
28 Sep 2021
ESMO 2021: Updates in hormone-sensitive prostate cancer
Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Cast...
ESMO 2021: Updates in hormone-sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Castro )
28 Sep 2021
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSC...
Dr Pascale Tomasini and Dr Catherine Shu
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )
27 Sep 2021
ESMO 2021: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
27 Sep 2021
Quality of life and safety in novel therapies for prostate cancer
Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal
Quality of life and safety in novel therapies for prostate cancer ( Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal )
24 Sep 2021
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally a...
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
24 Sep 2021
Enzalutamide plus androgen deprivation therapy prolongs survival in men with met...
Prof Andrew Armstrong - Duke University, Durham, USA
Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )
24 Sep 2021
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve ef...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2021
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal c...
Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )
23 Sep 2021
Adding abiraterone acetate plus prednisolone to standard therapy lengthens survi...
Prof Nick James - The Institute of Cancer Research, London, UK
Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer ( Prof Nick James - The Institute of Cancer Research, London, UK )
23 Sep 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuva...
Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute...
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
21 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with ...
Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021
Anti-cancer drug price regulation in India: Financial implications and annual sa...
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Anti-cancer drug price regulation in India: Financial implications and annual savings to patients ( Dr Krishnamani Kalpathi  - American Oncology Institute, Hyderabad, India )
20 Sep 2021
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) w...
Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Sep 2021
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausa...
Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
20 Sep 2021
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduct...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of adv...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )
19 Sep 2021
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer
Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Hou...
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )
19 Sep 2021
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...
Prof Hope Rugo - University of California San Francisco, San Francisco, USA
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )
19 Sep 2021
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-l...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
18 Sep 2021
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...
Prof Nadia Harbeck - University of Munich, Munich, Germany
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
18 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resecte...
Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma ( Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA )
18 Sep 2021
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical ...
Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, US...
Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal -  University of Utah School of Medicine, Salt Lake CIty, USA )
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021
Long-term outcomes and complications in cancer patients who have recovered from ...
Dr David Pinato - Imperial College London, London, UK
Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )
17 Sep 2021
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )
17 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pl...
Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )
17 Sep 2021
OncoAlert and ecancer - ESMO 2021 preview
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Sep 2021